ClinicalTrials.gg
CompletedNCT03460158Updated Sep 27, 2024Results posted

Prospective Evaluation of Facial Cosmetic Procedures

A Phase 4 interventional study of Restylane-L® and Restylane-L® Lyft in Cosmetic Techniques, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to female participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-27.

Sponsored by University of Pennsylvania · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
101
Allocation
Not applicable
Ages
40 Years to 65 Years
Sex
Female
01

Study summary

A prospective, trial to quantitatively and qualitatively compare the dermal fillers for the treatment of age related aesthetic changes.

Read the detailed description

Dermal fillers have been approved for the treatment of age related aesthetic changes, including facial volume loss, and attenuation of the static and dynamic rhytid. Despite widespread use of volumizing fillers there is little data quantifying the subjective benefit of these minimally invasive treatments from the patient perspective. Furthermore, there is little data comparing the subjective benefit with true objective volumetric results. Such data will provide much needed information for patient counselling and treatment optimization for patient perceived outcomes.

This study is to determine the patient reported outcomes of three different dermal fillers and establish the volumetric changes over 90 days. Screening will be performed during the patient's office visit. Approximately 100 patients will be enrolled. Patients will participate up to 90 days (Day 1, 14 days, 28 days, and 90 days).

02

Conditions studied

  • Cosmetic Techniques

Keywords

  • facial filler
  • Retylane
  • aesthetic improvement
  • volumizing fillers
03

In context

Lead sponsor

University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 233 are open to participants now.

Of its 159 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients 40 - 65 years of age

Exclusion criteria

Exclusion Criteria:

  • Male patients
  • Prior surgical facial rejuvenation procedures
  • Facelift
  • Neck lift
  • Blepharoplasty
  • Facial fat grafting
  • Prior minimally invasive rejuvenation procedure ≤ 12 months
  • Known to devices or drugs used in this study
  • Facial paralysis
  • Congenital facial asymmetry
  • Pregnant women
  • Patient actively taking blood thinners
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Restylane-L®, Restylane-L® Lyft, and Restylane Silk®

    Hyaluronic acid

    Drug: Restylane-L® · Drug: Restylane-L® Lyft · Drug: Restylane Silk®

Interventions

  • DrugRestylane-L®

    Restylane-L® for the indication for mid-to-deep dermal implantation for moderate to severe facial wrinkles and folds, such as nasolabial folds.

    Also known as: Hyaluronic acid gel

  • Restylane-L® Lyft is for the indication of implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds and malars (cheek/cheek bone area).

    Also known as: Hyaluronic acid gel

  • Restylane Silk® is for the indication for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.

    Also known as: Hyaluronic acid gel

06

What researchers measure

Primary outcomes

  1. Patient Satisfaction With Validated FACE-Q Aesthetics Survey

    Absolute Change of the Patient Satisfaction using the validated FACE-Q Aesthetics questionnaire for patient reported assessment of treatment by domain. The absolute change from the patient reported outcome score prior to injection to the patient reported score immediate post-injection. Increase in numeric value indicates the larger patient reported improvement, except for psychosocial distress module where a decrease in numeric value indicates patient improvement. Maximum change 99 and Minimum Change 0.

    Time frame: 2 week post injections

Secondary outcomes

  1. Correlate Patient Satisfaction With Volumetric Measurements

    Linear correlation of relative volumetric change over relative patient satisfaction scale change. These values are reported as correlation coefficients and are unit less.

    Time frame: upto 90 days

  2. Volumetric Changes of Treatment

    3-dimensional photography to measure volumetric changes in each treatment

    Time frame: immediately post injection, 2 weeks, 4 weeks, and 12 weeks

07

Results

Posted Sep 27, 2024

Participant flow

Participant flow — Overall Study
MilestoneRestylane-L®, Restylane-L® Lyft, and Restylane Silk®
Started101
Completed101
Not completed0

Outcome measures

PrimaryPatient Satisfaction With Validated FACE-Q Aesthetics Survey

Absolute Change of the Patient Satisfaction using the validated FACE-Q Aesthetics questionnaire for patient reported assessment of treatment by domain. The absolute change from the patient reported outcome score prior to injection to the patient reported score immediate post-injection. Increase in numeric value indicates the larger patient reported improvement, except for psychosocial distress module where a decrease in numeric value indicates patient improvement. Maximum change 99 and Minimum Change 0.

Time frame:
2 week post injections
Reported as:
Median · score on a scale
Patient Satisfaction With Validated FACE-Q Aesthetics Survey
score on a scaleRestylane-L®, Restylane-L® Lyft, and Restylane Silk®
Satisfaction with Facial Appearance. (Maximum change 99 and Minimum Change 0).28.0 (17.0 to 41.0)
Aging Appraisal. (Maximum change 99 and Minimum Change 0).24.0 (8.5 to 41.5)
Appraisal of Lines: Nasolabial Folds. (Maximum change 99 and Minimum Change 0).36.0 (12.0 to 58.0)
Appraisal of Lines: Marionette Lines. (Maximum change 99 and Minimum Change 0).36.0 (19.0 to 58.0)
Satisfaction with Lips. (Maximum change 99 and Minimum Change 0).23.5 (4.5 to 41.0)
Satisfaction with Cheekbones. (Maximum change 99 and Minimum Change 0).32.0 (17.0 to 53.5)
Satisfaction with Cheeks. (Maximum change 99 and Minimum Change 0).43.0 (23.0 to 60.0)
Satisfaction with Lower Face and Jawline. (Maximum change 99 and Minimum Change 0).35.0 (20.0 to 55.0)
Psychological Function. (Maximum change 99 and Minimum Change 0).13.0 (0.0 to 31.0)
Social Function. (Maximum change 99 and Minimum Change 0).8.0 (0.0 to 29.0)
Appearance-Related Psychosocial Distress. (Maximum change 99 and Minimum Change 0).-12.0 (-29.0 to 0.0)
SecondaryCorrelate Patient Satisfaction With Volumetric Measurements

Linear correlation of relative volumetric change over relative patient satisfaction scale change. These values are reported as correlation coefficients and are unit less.

Time frame:
upto 90 days
Reported as:
Number · correlation coefficient (unit less)
Correlate Patient Satisfaction With Volumetric Measurements
correlation coefficient (unit less)Restylane-L®, Restylane-L® Lyft, and Restylane Silk®
2 weeks post injection0.0226 (-0.2779 to 0.3232)
4 weeks post injection-0.1796 (-0.4691 to 0.1099)
12 weeks post injection-0.3692 (-0.5934 to -0.1451)
Statistical analysis
  • Restylane-L®, Restylane-L® Lyft, and Restylane Silk® · t-test, 2 sided · p = 0.8822 · Mean difference (final values): 0.023
  • Restylane-L®, Restylane-L® Lyft, and Restylane Silk® · t-test, 2 sided · p = 0.2223 · Mean difference (final values): -0.180
  • Restylane-L®, Restylane-L® Lyft, and Restylane Silk® · t-test, 2 sided · p = 0.0015 · Mean difference (final values): -0.369
SecondaryVolumetric Changes of Treatment

3-dimensional photography to measure volumetric changes in each treatment

Time frame:
immediately post injection, 2 weeks, 4 weeks, and 12 weeks
Reported as:
Median · cc
Volumetric Changes of Treatment
ccRestylane-L®, Restylane-L® Lyft, and Restylane Silk®
post injection9.86 (7.37 to 12.6)
2 weeks8.80 (6.30 to 11.0)
4 weeks7.63 (5.85 to 10.6)
12 weeks5.79 (3.20 to 9.38)

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Restylane-L®, Restylane-L® Lyft, and Restylane Silk®0/101 (0%)0/101 (0%)0/101 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Restylane-L®, Restylane-L® Lyft, and Restylane Silk®
Median53.2 (49.1 to 56.9)
Sex: Female, Male
Sex: Female, Male(Participants)Restylane-L®, Restylane-L® Lyft, and Restylane Silk®
Female101
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Restylane-L®, Restylane-L® Lyft, and Restylane Silk®
Race — African American/Black8
Race — Caucasian/White92
Race — Asian1
BMI
BMI(kg/m^2)Restylane-L®, Restylane-L® Lyft, and Restylane Silk®
Median24.4 (21.8 to 27.6)
Smoking History
Smoking History(Participants)Restylane-L®, Restylane-L® Lyft, and Restylane Silk®
Never62
Current11
Former27
Unknown1
08

Study locations

1 site
  • University of Pennsylvania Health System
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Feb 2024, 42 months.

Results were first posted in Sep 2024, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2017
First posted
Mar 9, 2018
StartActual
Aug 21, 2020
Primary completionActual
Feb 28, 2024
CompletionActual
May 29, 2024
Results first posted
Sep 27, 2024
Last update
Sep 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03460158
Collaborators
Galderma R&D
Responsible party
Sponsor
First posted
Mar 9, 2018
Start date
Aug 21, 2020
Primary completion
Feb 28, 2024
Completion
May 29, 2024
Results posted
Sep 27, 2024
Last update
Sep 27, 2024

Study contacts

Ivona Percec, MD,PhD
principal investigator · University of Pennsylvania Health System

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronic Acid

Start the discussion